Who is sponsoring NCT05941884?

NCT05941884 is sponsored by Assiut University.

What drugs are being tested in NCT05941884?

Interventions in NCT05941884: Immunohistochemistry staining,, microscopic examination of urine.

What condition does NCT05941884 study?

NCT05941884 studies Schistosoma Haematobium.

Is NCT05941884 still recruiting?

NCT05941884 is currently not yet recruiting. Last updated 12 July 2023.

Last reviewed 2023-07-12 · How we verify

NCT05941884

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.

Not yet recruiting Last updated 12 July 2023

What this trial tests

trial testing Immunohistochemistry staining, in Schistosoma Haematobium in 120 participants. Not yet recruiting.

Timeline

1 October 2023

Primary endpoint
30 June 2025

30 October 2027

Quick facts

Lead sponsor	Assiut University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	120
Start date	1 October 2023
Primary completion	30 June 2025
Estimated completion	30 October 2027
Sites	1 location across Egypt

Drugs / interventions tested

Immunohistochemistry staining,
microscopic examination of urine

Conditions studied

Schistosoma Haematobium — all drugs for Schistosoma Haematobium →

Sponsor

Assiut University

Who can join

30 and older, any sex, with Schistosoma Haematobium. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Schistosomiasis is the second most common parasitic infection affecting humans, endemic in the Middle East, especially Egypt (1), and in 42 African countries (2). There are 5 main species infecting humans: S. mansoni, S. haematobium, S. japonicum, S. intercalatum, and S. mekongi. S. haematobium is responsible for chronic urogenital infections that may cause serious complications (3). Urinary schistosomiasis is mostly borne in rural and agricultural communities, according to WHO (4)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05941884 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 12 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05941884.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing